Related Experiment Video
Updated: Aug 26, 2025
Profiling of Estrogen-regulated MicroRNAs in Breast Cancer Cells
Published on: February 21, 2014
Harnessing tumorous flaws for immune supremacy: is miRNA-155 the weak link in breast cancer progression?
Samantha Sharma1, Mateusz Opyrchal2,3, Xiongbin Lu1,3
1Department of Medical and Molecular Genetics and.
Abstract:
With the advent of immune checkpoint blockade (ICB) therapy, treatment strategies for late-stage cancers have seen a radical advancement. In this issue of the JCI, Wang et al. characterize the functional role of miR-155 in breast cancer and its potential in harnessing the efficacy of immunotherapy. The study reports that high expression levels of miR-155 in breast cancer cells downregulated suppressor of cytokine signaling 1 (SOCS1), increased the phosphorylated STAT1 (pSTAT1)/pSTAT3 ratio, and thereby stimulated chemoattractants for tumor infiltration of effector T cells. Moreover, miR-155 overexpression set the stage for ICB therapy via increased programmed death ligand 1 (PD-L1) expression on cancer cells and enhanced immunological memory response via the release of miR-155-containing extracellular vesicles. Collectively, these data suggest that miR-155 is a strong candidate as a prognostic biomarker for ICB therapy.
Insights
MicroRNA-155 (miR-155) enhances immunotherapy for breast cancer by increasing T cell infiltration and immune memory. High miR-155 levels may predict patient response to immune checkpoint blockade therapy.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Immune checkpoint blockade (ICB) therapy has revolutionized late-stage cancer treatment.
- Understanding molecular mechanisms that enhance ICB efficacy is crucial for optimizing cancer immunotherapy.
Purpose of the Study:
- To investigate the functional role of microRNA-155 (miR-155) in breast cancer.
- To explore the potential of miR-155 in improving the effectiveness of immunotherapy.
Main Methods:
- Analysis of miR-155 expression levels in breast cancer cells.
- Assessment of downstream signaling pathways, including SOCS1 and STAT1/STAT3.
- Evaluation of T cell infiltration and immune memory responses.
- Investigation of programmed death ligand 1 (PD-L1) expression.
Main Results:
- High miR-155 expression downregulated suppressor of cytokine signaling 1 (SOCS1).
- miR-155 increased the phosphorylated STAT1 (pSTAT1)/pSTAT3 ratio, promoting T cell chemoattraction.
- Overexpression of miR-155 enhanced programmed death ligand 1 (PD-L1) expression on cancer cells.
- miR-155 facilitated enhanced immunological memory via extracellular vesicles.
Conclusions:
- miR-155 plays a significant role in promoting anti-tumor immunity.
- miR-155 can enhance the efficacy of immune checkpoint blockade therapy in breast cancer.
- miR-155 is a potential prognostic biomarker for predicting response to ICB therapy.
